Nektar Therapeutics (NKTR) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $71.04 +10.33%
EPS Growth %: +26.6%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
CRMT, More
EPS Growth %: +26.6%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- Bending Spoons closes IPO, raises ~$954M on Nasdaq
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
